RNS Number : 4656J
Proximagen Neuroscience Plc
31 March 2010
|
For immediate release
|
31 March 2010
|
PROXIMAGEN NEUROSCIENCE PLC
("Proximagen" or "the Company")
GRANT OF NEW SHARE OPTIONS
London, UK, 31 March 2010 - Proximagen Neuroscience plc (LSE: PRX) announces that on 30 March 2010, Kenneth Mulvany, the Chief Executive Officer, and James Hunter, the Finance Director, were awarded share options under the Company's share option scheme. The options were granted over the Company's ordinary 1p shares and are exercisable at an exercise price of 140p, subject to the achievement of targets related to the increase in the Company's share price above 140p.
The closing price of Proximagen Neuroscience plc shares on 30 March 2010 was 107.5p.
Following these awards Mr. Mulvany and Mr. Hunter now hold the following numbers of share options:
|
|
Share option holding prior to the award
|
New share options granted
|
Total share option holding after the award
|
Share options held as % of issued capital
|
|
Kenneth Mulvany
|
-
|
1,720,000
|
1,720,000
|
3.0%
|
|
James Hunter
|
365,302
|
680,000
|
1,045,302
|
1.8%
|
Enquiries
|
Proximagen Neuroscience plc
|
Phone: +44 (0)20 7848 6938
|
|
Kenneth Mulvany, Chief Executive Officer
|
|
|
James Hunter, Finance Director
|
|
|
|
|
|
Evolution Securities Limited (NOMAD)
|
Phone: +44 (0)20 7071 4300
|
|
Stuart Andrews, Bobbie Hilliam, Tim Redfern
|
|
|
|
|
|
Pelham Bell Pottinger
|
Phone: +44 (0)20 7861 3800
|
|
Charles Cook, Dan de Belder, Zoë Pocock
|
|
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBLGDXRXXBGGG